Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-Resistance With Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-15-1169
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)